Daclizumab

Drug Profile

Daclizumab

Alternative Names: BIIB-019; DAC HYP; Dacliximab; Daclizumab high-yield process; Daclizumab HYP; HAT antibody; Humanised anti-Tac antibody; R35; RO 247375; SMART anti-Tac antibody; Zenapax; Zinbryta

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PDL BioPharma
  • Developer AbbVie; Biogen; Dana-Farber Cancer Institute; National Cancer Institute (USA); PDL BioPharma
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis; Renal transplant rejection
  • Discontinued Asthma; Graft-versus-host disease; Haematological malignancies; Immune-mediated uveitis; Liver transplant rejection; Psoriasis; Tropical spastic paraparesis; Type 1 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 07 Jul 2017 EMA’s Pharmacovigilance Risk Assessment Committee does not recommend use of daclizumab for the treatment of highly active, relapsing Multiple sclerosis
  • 22 Apr 2017 Adverse events and efficacy data from phase IIb (SELECT and SELECTION) trials in Multiple sclerosis presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 18 Apr 2017 Phase-III clinical trials in Multiple sclerosis (Recurrent) in Puerto Rico (SC) (NCT02881567)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top